---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030185"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:10:50.304385+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics awards 235,000 RSUs to CEO MacLean and interim CFO Jin

## Summary
- CEO Alexandra MacLean receives 170,000 RSUs; Interim CFO/COO David Jin receives 65,000 RSUs.
- RSUs vest in four equal installments on 9/30/24, 12/31/24, 9/20/25, and 9/20/26, subject to continued service.
- Settlement deferred until the earlier of Jan 10 after termination of service or a Change in Control.
- Awards granted under the company's 2015 Incentive Plan as amended.

## SEC filing metadata
- accession: 0001437749-24-030185
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774924030185/0001437749-24-030185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774924030185/atxi20240927_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030185
- JSON: https://secwatch.observer/filing/0001437749-24-030185.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.